相关实验视频
Updated: May 8, 2025

09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
48
蒂尔泽帕提德的胰腺安全性及其对小岛细胞功能的影响:系统性审查和元分析
A B M Kamrul-Hasan1, Sunetra Mondal2, Deep Dutta3
1Department of Endocrinology Mymensingh Medical College Mymensingh Bangladesh.
Obesity science & practice
|December 25, 2024
概括
蒂尔泽帕提德是一种双重GLP-1和GIP激动剂,其胰腺炎的安全性与安慰剂和GLP-1受体激动剂相当. 这一元分析证实了蒂尔泽帕提德对岛屿细胞功能和胰岛素耐药性的益处.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 临床试验分析
背景情况:
- 内生葡萄糖样-1 (GLP-1) 和依赖葡萄糖的胰岛素型多 (GIP) 是岛屿细胞功能的关键调节剂.
- GLP-1受体激动剂 (GLP-1RAs) 与胰腺炎风险增加有关;关于双重GLP-1/GIP激动剂蒂尔泽帕提德的数据有限.
- 在随机对照试验 (RCT) 中,没有任何全面的元分析评估过tirezepatide的胰腺安全性和对小岛细胞功能的影响.
研究的目的:
- 为了评估与安慰剂,胰岛素和GLP-1RAs相比,蒂尔泽帕提德的胰腺安全性.
- 评估蒂尔泽帕提德对岛屿细胞功能标记物的作用,包括胰岛素,C-和葡萄糖.
- 通过同居稳定模型评估 (HOMA2-IR) 确定蒂尔泽帕提德对胰岛素耐药性的影响.
主要方法:
- 通过对电子数据库的系统搜索,确定了与泽帕提德与安慰剂或活性比较剂进行比较的RCT.
- 主要结果:判断证实了胰腺炎.
- 二次结局:血清胰腺氨酶,脂酶,胰岛素,C-,葡萄糖和HOMA2-IR的变化.
主要成果:
- 十七个RCT (14,645名受试者) 显示,提尔泽帕提德与安慰剂和GLP-1RA具有类似的胰腺炎风险.
- 蒂尔泽帕提德比安慰剂和胰岛素更多地增加了胰腺粉酶和脂酶水平,但在15毫克时显示了与GLP-1RA相似的脂酶增加.
- 与安慰剂和GLP-1RA相比,蒂尔泽帕提德显示出更大的禁食胰岛素,C-,葡萄糖和HOMA2-IR的减少.
结论:
- 提尔泽帕提德在胰腺炎风险方面表现出良好的安全性.
- 该药物显著改善了小岛细胞功能标记物.
- 蒂尔泽帕提德有效降低胰岛素耐药性,支持其治疗潜力.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Acute Pancreatitis II: Clinical Manifestations and Management
65
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
65
Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1000
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1000
Chronic Pancreatitis II: Collaborative Care
46
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
46

